| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/04/2001 | WO2000069429A3 Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
| 10/04/2001 | WO2000053231A3 Fatty acid-anticancer conjugates and uses thereof |
| 10/04/2001 | WO2000047625A9 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 10/04/2001 | WO2000043039A9 Vaccine-mediated treatment of neurological disorders |
| 10/04/2001 | WO2000040240A9 Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
| 10/04/2001 | WO2000039279A9 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 10/04/2001 | WO2000015178A9 Computer implemented pharmacokinetics method and program |
| 10/04/2001 | WO1999061428A9 Quinazolines for treating brain tumor |
| 10/04/2001 | US20010027565 Capable of binding envelope protein of hepatitis virus; therapy and/or diagnostic tool for hepatitis infection |
| 10/04/2001 | US20010027256 Method for the preparation of citalopram |
| 10/04/2001 | US20010027251 Mimic or modulate activity of wild-type nucleic acids thereby affecting protein production or activity |
| 10/04/2001 | US20010027216 Method for preventing hormone induced adverse effects |
| 10/04/2001 | US20010027215 Pulse administering of a C1-C4 substituted and/or phenyl substituted carboxylic acid and salts and a carrier or diluent to stimulate cells in treating blood disorders, e.g. sickle cell anemia, thalassemia, blood loss etc. |
| 10/04/2001 | US20010027214 Stable and nonhygroscopic salts to form tablets, capsules, powders, etc. suitable for dietary/nutritional humans supplements and a feed supplement for veterinary medicine; high-energy metabolism; cardiovascular systems |
| 10/04/2001 | US20010027213 Use of pyrethroid compounds to promote hair growth |
| 10/04/2001 | US20010027212 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 10/04/2001 | US20010027211 Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents |
| 10/04/2001 | US20010027210 Administering a synergistic mixture of a compound of the xanthenone acetic acid class (5,6-dimethylxanthenone-4-acetic acid) and either paclitaxel or docetaxel; antitumor and -carcinogenic agents |
| 10/04/2001 | US20010027209 Canolide analogues or derivatives of 2-oxo-6,7,8,10,11,12-2H-benzo(1,2-b:3,4-b':5,6-b")tripyran; treating and prevention of mycobacterium infections; tuberculosis; HIV; viricides |
| 10/04/2001 | US20010027207 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation; anticarcinogenic, -diabetic, -proliferative and -inflammatory agents; vascular system disorders |
| 10/04/2001 | US20010027206 Administering a mixture of sodium co-transport dependent aminocarboxylic acids to saturate sodium-dependent amino carboxylic acid transport mechanisms of cell plasma membranes; antiischemic, -hypoxic, cardiotonic agents |
| 10/04/2001 | US20010027205 Benzimidazole derivatives, e.g. thiabendazole, benomyl and carbendazim; antiproliferative and -growth agents; extending the life span of an animal having leukemia |
| 10/04/2001 | US20010027204 D-cycloserine (d-4-amino-3-isooxazolidinone) and prodrugs; glycine B partial agonists; cognition activators; Alzheimer's disease |
| 10/04/2001 | US20010027203 Chemical complex comprising a pyridine carboxy derivative and an H2 histamine receptor antagonist |
| 10/04/2001 | US20010027202 Antitumor and -carcinogenic agents; solid cancers, e.g carcinomas of the lungs, pancreas, thyroid, bladder or color, myeloid disorders, e.g. leukemia or adenomas, e.g villous colon adenoma |
| 10/04/2001 | US20010027201 Non-systemic control of parasites |
| 10/04/2001 | US20010027200 PPARgamma modulators |
| 10/04/2001 | US20010027199 Administering a Tumor Necrosis Factor-alpha inhibitor from the group of metalloproteinase inhibitors, quinolones, corticoids, thalidomide, lazaroides, pentoxyphyllines, hydroxamic and carbocyclic acids; spinal disk hernias |
| 10/04/2001 | US20010027197 Antiproliverative, -carcinogenic and -tumor agents; mitogenesis-activated protein kinase inhibitors; noncytotoxic; binding with high affinity at the adenosine triphosphate binding site of the kinases |
| 10/04/2001 | US20010027196 Adenosine receptor ligands and their use in the treatment of disease |
| 10/04/2001 | US20010027194 Novel compounds useful as neuro-protective agents |
| 10/04/2001 | US20010027192 A gastrointestinal mucosa-adherent solid comprising an anti-Helicobacter pylori antibiotic and a proton pump inhibitor (antiulcer); synergistic; potentiation; side effect reduction |
| 10/04/2001 | US20010027191 Soluble forms of amoxicillin and treatment of animals |
| 10/04/2001 | US20010027190 Plant sterols and stanols and a mixture of two or three different emulsifiers of given HLB ranges; for low fat, fat-free, and triglyceride-free foods; good mouthfeel |
| 10/04/2001 | US20010027189 Progestogen-anti-progestogen regimens |
| 10/04/2001 | US20010027188 Ophthalmic composition for keratoconjunctivitis sicca (dry eye) |
| 10/04/2001 | US20010027187 Such as hydroxyethylated bis(trimethoxysilylpropyl)amine as well as modified polyamines for use as silylating agents in surface treatment of silica and in formation of nucleic acid arrays |
| 10/04/2001 | US20010027186 Phosphono-carboxylate compounds for treating amyloidosis |
| 10/04/2001 | US20010027185 Methods and compositions for treating inflammatory response |
| 10/04/2001 | US20010027184 Serine/threonine protein kinase (H-SGK2) |
| 10/04/2001 | US20010027176 Cyclooxygenase inhibitor |
| 10/04/2001 | US20010027175 Inhibiting tumor necrosis factor-alpha (TNF-a) for treating nerve conditions such as sciatica by administering antiinflammatory agent etanercept or infliximab |
| 10/04/2001 | US20010026934 Conversion of compactin to pravastatin by actinomadura |
| 10/04/2001 | US20010026814 Composition for and method of reducing low density lipoprotein cholesterol concentration |
| 10/04/2001 | US20010026808 Non-steroidal anti inflammatory drug and misoprostol in the form of non-breakable coated pellets; side effect reduction |
| 10/04/2001 | US20010026794 Two heterologous DNA encoding gene products; prolonged half-life |
| 10/04/2001 | US20010026788 Method of producing a nicotine medicament and a medicament made by the method |
| 10/04/2001 | EP1138773A2 Use of plasmids for the manufacture of a composition for vaccine treatment by human and animal |
| 10/04/2001 | EP1138690A1 A process for the isolation of 2-deoxy ecdysterone from Zoanthus sp and its use for the preparation of a medicament for inducing labour or abortion |
| 10/04/2001 | EP1138682A1 Novel water soluble c-ring analogues of 20 (s)-camptothecin |
| 10/04/2001 | EP1138680A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
| 10/04/2001 | EP1138678A2 Process for making N-((4-phenyl) methylphenyl) piperazines |
| 10/04/2001 | EP1138677A1 Process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]-thiazepine and application to the synthesis of tianeptine |
| 10/04/2001 | EP1138674A1 Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide |
| 10/04/2001 | EP1138673A2 Novel carbamates and ureas as modifiers of multi-drug resistance |
| 10/04/2001 | EP1138333A1 Medicinal compositions for oral use |
| 10/04/2001 | EP1138332A1 Use of GABA B receptor agonists for the treatment of hyperkinesia and poriomania |
| 10/04/2001 | EP1138331A2 Stool marker |
| 10/04/2001 | EP1138330A1 Combination of trimebutine with an opioid analgesic |
| 10/04/2001 | EP1138329A2 Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions |
| 10/04/2001 | EP1138328A1 Naphthalene derivatives as CNS drugs |
| 10/04/2001 | EP1138327A1 Use of 2-(arylalkenyl)azacycloalkanes derivatives for treating stress-related gastrointestinal disorders |
| 10/04/2001 | EP1138326A1 Use of synthetic triglycerides based on conjugated linoleic acid in the preparation of agents for the treatment of catabolic conditions |
| 10/04/2001 | EP1138325A1 Use of synthetic triglycerides based on conjugated linoleic acid in the preparation of agents aiding tumour treatment |
| 10/04/2001 | EP1138324A1 Treatment of neurodegenerative conditions with nimesulide |
| 10/04/2001 | EP1138323A2 Resveratrol for the treatment of exfoliative eczema, acne or psoriasis |
| 10/04/2001 | EP1138320A2 Floating forms containing drug, polyvinyl acetate and polyvinyl pyrrolidone, their use and preparation |
| 10/04/2001 | EP1138314A2 Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues |
| 10/04/2001 | EP1138313A1 Proliposomes |
| 10/04/2001 | EP1137949A1 Assays for compounds which increase phospholipase a2 activity |
| 10/04/2001 | EP1137948A1 Methods and compositions to lower plasma cholesterol levels |
| 10/04/2001 | EP1137813A1 Method of drying a lactulose solution |
| 10/04/2001 | EP1137793A2 Novel nucleic acid transferring agents, compositions containing them and uses |
| 10/04/2001 | EP1137780A1 Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp |
| 10/04/2001 | EP1137773A2 Growth factor homolog zvegf3 |
| 10/04/2001 | EP1137771A2 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |
| 10/04/2001 | EP1137671A1 Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions |
| 10/04/2001 | EP1137664A2 Protein transduction system and methods of use thereof |
| 10/04/2001 | EP1137660A1 22s-hydroxycholesta-8,14-diene derivatives with meiosis regulating activity |
| 10/04/2001 | EP1137658A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES |
| 10/04/2001 | EP1137655A1 Macrolide intermediates in the preparation of clarithromycin |
| 10/04/2001 | EP1137653A1 Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same |
| 10/04/2001 | EP1137652A2 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same |
| 10/04/2001 | EP1137647A1 Thiourea inhibitors of herpes viruses |
| 10/04/2001 | EP1137646A1 Derivative of paroxetine |
| 10/04/2001 | EP1137645A2 Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group |
| 10/04/2001 | EP1137644A1 Benzofuran derivatives, their preparation and use |
| 10/04/2001 | EP1137642A1 Bis-sulfonamides |
| 10/04/2001 | EP1137640A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors |
| 10/04/2001 | EP1137639A1 Control of arthropods in animals |
| 10/04/2001 | EP1137638A2 Isoquinoline derivatives |
| 10/04/2001 | EP1137637A1 N-(2-phenyl-4-piperidinylbutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists |
| 10/04/2001 | EP1137636A1 Process for preparation of paroxetine maleate |
| 10/04/2001 | EP1137635A1 N-substituted 2-cyanopyrrolidines |
| 10/04/2001 | EP1137633A2 Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses |
| 10/04/2001 | EP1137632A1 Thiourea inhibitors of herpes viruses |
| 10/04/2001 | EP1137631A1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE |
| 10/04/2001 | EP1137628A1 Molecular scaffolds acting as templates comprising carbamate linkages |
| 10/04/2001 | EP1137621A1 Aldose reductase inhibitors and pharmaceutical compositions |
| 10/04/2001 | EP1137497A1 Apparatus for separating particles of cohesive material according to size and process |